Morgan Stanley upgraded Abivax (ABVX) to Overweight from Equal Weight with a price target of $71, up from $12.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABVX:
- Why Is Abivax Stock (ABVX) Up 490% Today?
- Abivax price target raised to $101 from $50 at Guggenheim
- Abivax price target raised to $70 from $42 at Piper Sandler
- Promising Phase 3 Results and Broad Market Potential Drive Buy Rating for Obefazimod
- Abivax price target raised to $95 from $33 at Citizens JMP